BDBM528116 N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(5-fluoro-2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide::US11180484, Example 53

SMILES COCc1nn(Cc2ccc(Cn3cc(F)ccc3=O)cc2)cc1C(=O)NCc1c(F)c(OC)ccc1C#N

InChI Key InChIKey=WONUSGGEAIADDP-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 528116   

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 1.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetPlasma serine protease inhibitor(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetSerine protease 1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent